Screener
Edgewise Therapeutics, Inc. EWTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Exercise of stock options | 12,173 | 2,261 |
| Payment of deferred offering costs | — | (38) |
| Net cash provided by financing activities | 12,173 | 2,223 |
| Net change in cash and cash equivalents | (27,937) | 8,255 |
| Cash and cash equivalents at beginning of period | 61,148 | 41,666 |
| Cash and cash equivalents at end of period | $33,211 | $49,921 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Property and equipment purchases included in accounts payable and accrued other expenses | $41 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s net change in cash?
- Edgewise Therapeutics, Inc. (EWTX) reported net change in cash of -$27.94M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s net change in cash changed year-over-year?
- Edgewise Therapeutics, Inc.'s net change in cash decreased by 438.4% year-over-year, from $8.26M to -$27.94M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Edgewise Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude